Reneo Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
I'm a member of the biotechnology research team at Jefferies, and it is my pleasure to introduce Gregory Flesher and Alex (multiple speakers).
Dorenbaum.
Thank you, [Nolan]. Good morning, everyone, or I guess -- is it afternoon? Still morning time, I guess, in New York. So thank you for attending our presentation or our discussion today.
So as I look around the room, I see a lot of folks that already know the story. So I'm probably not going to bore you with a walk through the deck. I would like to highlight just a few slides, and then we'll do sort of a fireside questions and answers for those people that have questions.
So Reneo Pharmaceuticals is a late-stage clinical development company. We're focusing entirely in orphan diseases. And within the orphan disease category, we're focusing more tightly on metabolic and mitochondrial diseases. And we have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
